NYSE:NNVC NanoViricides (NNVC) Stock Price, News & Analysis $2.24 +0.04 (+1.82%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$2.16▼$2.3550-Day Range$1.64▼$3.3052-Week Range$1.00▼$3.59Volume162,133 shsAverage Volume299,952 shsMarket Capitalization$26.45 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsTrends Get NanoViricides alerts: Email Address Ad Crypto 101 Media“Dollar Will Be Worth NOTHING” -MuskElon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…All you have to do is claim your free ticket to the event now… About NanoViricides Stock (NYSE:NNVC)NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases. It also offers NV-CoV-2 Solution for injection, infusion, and inhalation to treat severe cases that are not yet hospitalized would be best performed by an injection; and injectable solution can be delivered directly into the lungs as a fog created using standard portable battery operated nebulizer devices which enables action at the most important site of infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company provides Nanoviricide, a biomimetic platform technology designed to attack enveloped virus particles to deliver anti-viral payload into infected cells sparing uninfected cells to block replication cycle without toxicity. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.Read More NNVC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NNVC Stock News HeadlinesJuly 25 at 2:00 AM | americanbankingnews.comComparing NanoViricides (NYSE:NNVC) and Nuvectis Pharma (NASDAQ:NVCT)July 24, 2024 | proactiveinvestors.comNanoViricides spotlights lead drug candidate's potential as COVID therapyJuly 28, 2024 | Crypto 101 Media (Ad)“Dollar Will Be Worth NOTHING” -MuskElon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…July 19, 2024 | americanbankingnews.comNanoViricides (NYSE:NNVC) Stock Rating Lowered by StockNews.comJuly 11, 2024 | proactiveinvestors.comNanoViricides discusses lead program and next stepsJuly 1, 2024 | proactiveinvestors.comNanoViricides hails broad potential of lead antiviral drug as it prepares to begin first Phase II trialJune 24, 2024 | proactiveinvestors.comNanoViricides hails the potential of NV-387 in combatting bird flu virus H5N1June 20, 2024 | proactiveinvestors.comNanoViricides says antiviral drug candidate shows promise in protecting lungs against Influenza AJuly 28, 2024 | Crypto 101 Media (Ad)“Dollar Will Be Worth NOTHING” -MuskElon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…June 11, 2024 | proactiveinvestors.comNanoViricides antiviral candidate 'may be first effective oral nanomedicine'June 4, 2024 | proactiveinvestors.comNanoViricides says lead asset exhibits desirable blood concentration profile for infrequent dosingMay 29, 2024 | finance.yahoo.comA First-In-Class, Broad-Spectrum Antiviral Agent Intending To Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and MoreMay 29, 2024 | proactiveinvestors.comNanoViricides CEO says lead asset NV-387 could be ‘holy grail' of antiviral medicinesMay 23, 2024 | proactiveinvestors.comNanoViricides taps Aagami to seek out licensing and partnership opportunitiesMay 23, 2024 | finance.yahoo.comNanoViricides Bolsters Partnership Efforts - Engages Aagami Inc.May 21, 2024 | proactiveinvestors.comNanoViricides could generate ‘antiviral superdrug' for multiple diseases, analysts believeMay 20, 2024 | finanznachrichten.deNanoViricides, Inc.: Lethally RSV Infected Animals Orally Treated with NV-387 Showed Normal Lung Histology, Indicating Potential CureMay 20, 2024 | proactiveinvestors.comNanoViricides reports strong antiviral activity of NV-387 against RSVSee More Headlines Receive NNVC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NanoViricides and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today7/28/2024Fiscal Year End6/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSE:NNVC CUSIPN/A CIK1379006 Webwww.nanoviricides.com Phone(203) 937-6137Fax203-859-5095Employees7Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,590,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-74.66% Return on Assets-66.51% Debt Debt-to-Equity RatioN/A Current Ratio4.32 Quick Ratio4.32 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.28 per share Price / Book1.75Miscellaneous Outstanding Shares11,810,000Free Float11,271,000Market Cap$26.45 million OptionableOptionable Beta0.97 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Anil R. Diwan Ph.D. (Age 65)Executive Chairman, President, CEO & Secretary Comp: $400kMs. Meeta R. Vyas B.S. (Age 65)M.B.A., SB, MBA, Chief Financial Officer Comp: $129.6kDr. Randall W. Barton Ph.D. (Age 77)Chief Scientific Officer Key CompetitorsOramed PharmaceuticalsNASDAQ:ORMPSagimet BiosciencesNASDAQ:SGMTAEON BiopharmaNASDAQ:AEONTiziana Life SciencesNASDAQ:TLSALifeVantageNASDAQ:LFVNView All CompetitorsInstitutional OwnershipMoss Adams Wealth Advisors LLCBought 15,000 shares on 7/23/2024Ownership: 0.127%View All Institutional Transactions NNVC Stock Analysis - Frequently Asked Questions How have NNVC shares performed this year? NanoViricides' stock was trading at $1.02 at the start of the year. Since then, NNVC shares have increased by 119.6% and is now trading at $2.24. View the best growth stocks for 2024 here. How were NanoViricides' earnings last quarter? NanoViricides, Inc. (NYSE:NNVC) announced its quarterly earnings data on Wednesday, May, 15th. The company reported ($0.16) earnings per share (EPS) for the quarter. When did NanoViricides' stock split? NanoViricides shares reverse split on Tuesday, September 24th 2019. The 1-20 reverse split was announced on Thursday, September 12th 2019. The number of shares owned by shareholders was adjusted after the market closes on Monday, September 23rd 2019. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. Who are NanoViricides' major shareholders? Top institutional investors of NanoViricides include Moss Adams Wealth Advisors LLC (0.13%). View institutional ownership trends. How do I buy shares of NanoViricides? Shares of NNVC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:NNVC) was last updated on 7/28/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredJ.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal war...Behind the Markets | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NanoViricides, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NanoViricides With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.